Welcome to the e-CCO Library!

P356: Czech experience with treatment of Crohn´s disease perianal fistulas by allogenic mesenchymal stem cell
Year: 2022
Source: ECCO'22
Authors: Serclova, Z.(1);Lengálová, M.(1);Zusková, P.(1);Tremerová, A.(1);Drvostepova, L.(1);
Created: Friday, 11 February 2022, 3:52 PM
P356: Efficacy and safety of certolizumab pegol in Crohn’s disease patients with loss of response or intolerance to previous anti-TNF
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

I. Ferrer Bradley*1, I. Marín2, N. Maroto1, M. Mora1, E. Hinojosa1, B. López2, L. Menchén2, J. Hinojosa1

Created: Friday, 22 February 2019, 9:49 AM
P356: Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in paediatric patients with inflammatory bowel disease: a multi-centre cohort study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Toita*1, H. Tanaka2, K. Arai3, H. Shimizu3, D. Abukawa4, T. Kobayashi5, N. Yoshimura6, S. Tanida7, E. Hosoi8

Created: Friday, 22 February 2019, 9:41 AM
P356: The role of endoscopic activity in the coagulation profile of clinical remission Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Andrade*, M. Azevedo, A. Carlos, C. Hashimoto, A. Sipahi, A. Damião, E. D´Amico, A. Leite

Created: Thursday, 21 February 2019, 9:14 AM
P356: Treatment with anakinra induces T cell production of IL22 and GI mucosal healing in an IL-10RA mutation patient
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Li J.1, Shouval D.2, Doty A.1, Snapper S.3, Glover S.*1

Created: Wednesday, 20 February 2019, 10:36 AM
P357 Importance of stool drug monitoring in anti-TNF-treated patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

P. Bacsur1, K. Szántó1, T. Madácsy1, D. Kata1, T. Ferenci2, M. Rutka1, A. Bálint1, R. Bor1, A. Fábián1, Á. Milassin1, G. Elekes3, Z. Szepes1, F. Nagy1, I. Földesi3, J. Maléth1, K. Farkas1, T. Molnár1

Created: Thursday, 30 January 2020, 10:12 AM
P357: A multi-institutional report of postoperative outcomes in Vedolizumab-Treated patients undergoing major abdominal operations for inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lightner A.*1, Mathis K.2, Sang Tse C.3, Pemberton J.1, Shen B.4, Kocklar G.4, Singh A.4, Parambir D.5, Eisenstein S.6, Stringfield S.5, Hudesman D.7, Remzi F.8, Loftus E.3

Created: Wednesday, 20 February 2019, 10:36 AM
P357: Do you think that complementary and alternative medicine use is frequent amongst inflammatory bowel disease patients: Forget it!—results from a comparative study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Rutka*1, T. Ferenci2, F. Nagy1, Z. Szepes1, K. Farkas1, A. Bálint1, R. Bor1, A. Milassin1, Z. Lénárt1, T. Molnar1

Created: Friday, 22 February 2019, 9:49 AM
P357: Healthcare and medication utilisation in Singapore adult inflammatory bowel disease patients receiving immunomodulators and biologics
Year: 2018
Source: ECCO '18 Vienna
Authors:

R.E.L. Gan1,2,3, C.K.Y. Ng1, W.C. Ong1, W.P.W. Chan2,3, B.J. Schwender2,3, S.C. Kong2,3, H.H. Shim2,3, K.L. Ling2,3, S.W. Chuah2,3, T.G. Lim1,3*

Created: Thursday, 21 February 2019, 9:14 AM
P357: Intestinal ultrasound as a promising non-invasive monitoring tool in patients with Ulcerative Colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Morão, B.(1)*;Nascimento, C.(1);Revés, J.(1);Abreu, B.(1);Bravo, A.C.(1);Saraiva, S.(1);Glória, L.(1);Torres, J.(1);Palmela, C.(1);Frias Gomes, C.(1);
Created: Friday, 14 July 2023, 11:05 AM
P357: Long-term outcomes of biologic therapy in Crohn’s disease complicated with internal fistulizing disease: BIOSCOPE study from GETECCU
Year: 2021
Source: ECCO'21 Virtual
Authors: Rodríguez-Lago, I.(1);Fernández-Clotet, A.(2,3);Mesonero, F.(4);García-Alonso, F.J.(5);Casanova, M.J.(6);Fernández-de la Varga, M.(7);Cañete, F.(8);de Castro, L.(9);Gutiérrez, A.(10);Sicilia, B.(11);Cano, V.(12);Merino, O.(13);Riestra, S.(14);González-Partida, I.(15);Surís, G.(16);Torrealba, L.(17);Ferreiro-Iglesias, R.(18);Castro, B.(19);Márquez, L.(20);Sobrino, A.(21);Elorza, A.(1);Calvet, X.(22);Varela, P.(23);Betoré, E.(24);Bujanda, L.(25);Lario, L.(26);Manceñido, N.(27);García-Sepulcre, M.(28);Iglesias, E.(29);Rodríguez, C.(30);Piqueras, M.(31);Ferrer Rosique, J.Á.(32);Lucendo, A.(33);Benítez, O.(34);García, M.(35);Olivares, D.(36);González-Muñoza, C.(37);Cabriada, J.L.(1);Domènech, E.(8);Barreiro-de Acosta, M.(18);
Created: Wednesday, 2 June 2021, 4:12 PM
P357: Monitoring of Thiopurines and Methotrexate in Inflammatory Bowel Disease: Are we Monitoring Too Frequently? A Cross Sectional Study.
Year: 2022
Source: ECCO'22
Authors: Liao, Y.W.(1);Oh, S.(1);Wright, A.(1);Evans, C.(1);Duff, C.(1);Farmer, A.(1);Fryer, A.(1);
Created: Friday, 11 February 2022, 3:52 PM
P357: Serological biomarkers of interstitial matrix and basement membrane remodelling correlate to disease activity in Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

L. Godskesen1, M. Lindholm2, J. Høg Mortensen2, A. Krag1, M. Karsdal2, T. Manon-Jensen2, J. Kjeldsen1

Created: Friday, 22 February 2019, 9:41 AM
P358 Predictors of response to faecal microbiota transplantation in patients with active ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Singh1, A. Sood1, V. Midha2, R. Mahajan1, N. Bansal3, K. Kaur4, D. Singh3

Created: Thursday, 30 January 2020, 10:12 AM
P358: An observational, prospective cohort study to evaluate the long term safety and effectiveness of intravenous CT-P13 (biosimilar of infliximab) in patients with Crohn’s Disease or Ulcerative Colitis
Year: 2021
Source: ECCO'21 Virtual
Authors: Cheon, J.H.(1);Kang, H.W.(2);Lee, S.J.(3);Kim, S.H.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P358: Efficacy of golimumab for the treatment of ulcerative colitis patients in clinical practice: a retrospective cohort study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Dufour G.*1, Altwegg R.1, Valats J.-C.1, Bismuth M.1, Funakoshi N.1, Gonzalez F.1, Caillo L.2, Pouderoux P.2, Blanc P.1, Pineton de Chambrun G.1

Created: Wednesday, 20 February 2019, 10:36 AM
P358: Factors associated with disability in inflammatory bowel disease (IBD): A cross-sectional study in outpatients
Year: 2018
Source: ECCO '18 Vienna
Authors:

J.M. Costa1*, D. Matos2, R. Costa1, B. Arroja1, R. Gonçalves1, J.B. Soares1

Created: Thursday, 21 February 2019, 9:14 AM
P358: Keeping it simple: How a streamlined referrals process reduces the time taken to initiate biologic therapy
Year: 2022
Source: ECCO'22
Authors: Granger, E.(1);Heyes, E.(2);Cahoon, E.(2);Riley, G.(2);Kwok, J.(2);Shuttleworth, E.(2);
Created: Friday, 11 February 2022, 3:52 PM
P358: Long-term clinical outcomes of intestinal Behçet's disease: a 30-year cohort study at a tertiary hospital in South Korea
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Park, J.(1)*;Park, S.J.(2);Park, J.J.(2);Kim, T.I.(2);Kim, W.H.(2);Cheon, J.H.(2);
Created: Friday, 14 July 2023, 11:05 AM
P358: Six-year adalimumab efficacy in steroid-dependent Crohn’s disease patients: a prospective ‘real-life’ study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Renna*1, M. Cappello2, R. Dimitri3, F. Mocciaro3, M. Mazza2, M. Giunta4, M. Mendolaro2, E. Orlando1, M. Affronti1, A. Craxì2, M. Cottone1, A. Orlando1

Created: Friday, 22 February 2019, 9:49 AM